Crescent Biopharma earnings were -$41.2M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest CBIO earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$21.8M, up 829.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CBIO reported annual earnings of -$37.9M, with 2.7% growth.
What were Crescent Biopharma's earnings last quarter?
Crescent Biopharma (NASDAQ: CBIO) reported Q2 2025 earnings per share (EPS) of -$4.93, up 69.19% year over year. Total CBIO earnings for the quarter were -$21.79 million. In the same quarter last year, Crescent Biopharma's earnings per share (EPS) was -$16.00.
As of the last Crescent Biopharma earnings report, Crescent Biopharma is currently losing money. Crescent Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$41.18 million, a 5.29% increase year over year.
What was CBIO's earnings growth in the past year?
As of Crescent Biopharma's earnings date in Q3 2025, Crescent Biopharma's earnings has grown year over year. CBIO earnings in the past year totalled -$41.18 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.